OBJECTIVE: Dissemination of preexposure prophylaxis (PrEP) is a priority for reducing new HIV infections, especially among vulnerable populations. However, there are limited data available on PrEP discontinuation following initiation, an important component of the PrEP cascade. DESIGN: Patients receiving PrEP within the San Francisco Department of Public Health Primary Care Clinics (SFPCC) are included in a PrEP registry if they received a PrEP prescription, were not receiving postexposure prophylaxis, and not known to be HIV-positive. METHODS: We calculated PrEP discontinuation for patients initiating PrEP at any time from January 2012 to July 2017 and evaluated their association with demographic and risk variables using Cox regression analysis. RESULTS: Overall, 348 patients received PrEP over the evaluation period. The majority (84%) were men, and the cohort was racially/ethnically diverse. The median duration of PrEP use was 8.3 months. In adjusted analysis, PrEP discontinuation was lower among older patients (aHR 0.89; 95% CI 0.80-0.99; P = 0.03); but higher among black patients (compared with white patients; aHR 1.87; 95% CI 1.27-2.74; P = 0.001), patients who inject drugs (aHR 4.80; 95% CI 2.66-8.67; P < 0.001), and transgender women who have sex with men (compared with MSM; aHR 1.94; 95% CI 1.36-2.77; P < 0.001). CONCLUSION: Age, racial/ethnic, and risk category disparities in PrEP discontinuation were identified among patients in a public health-funded primary care setting. Further efforts are needed to understand and address PrEP discontinuation among priority populations to maximize the preventive impact of PrEP, and reverse HIV-related disparities at a population level.
OBJECTIVE: Dissemination of preexposure prophylaxis (PrEP) is a priority for reducing new HIV infections, especially among vulnerable populations. However, there are limited data available on PrEP discontinuation following initiation, an important component of the PrEP cascade. DESIGN:Patients receiving PrEP within the San Francisco Department of Public Health Primary Care Clinics (SFPCC) are included in a PrEP registry if they received a PrEP prescription, were not receiving postexposure prophylaxis, and not known to be HIV-positive. METHODS: We calculated PrEP discontinuation for patients initiating PrEP at any time from January 2012 to July 2017 and evaluated their association with demographic and risk variables using Cox regression analysis. RESULTS: Overall, 348 patients received PrEP over the evaluation period. The majority (84%) were men, and the cohort was racially/ethnically diverse. The median duration of PrEP use was 8.3 months. In adjusted analysis, PrEP discontinuation was lower among older patients (aHR 0.89; 95% CI 0.80-0.99; P = 0.03); but higher among black patients (compared with white patients; aHR 1.87; 95% CI 1.27-2.74; P = 0.001), patients who inject drugs (aHR 4.80; 95% CI 2.66-8.67; P < 0.001), and transgender women who have sex with men (compared with MSM; aHR 1.94; 95% CI 1.36-2.77; P < 0.001). CONCLUSION: Age, racial/ethnic, and risk category disparities in PrEP discontinuation were identified among patients in a public health-funded primary care setting. Further efforts are needed to understand and address PrEP discontinuation among priority populations to maximize the preventive impact of PrEP, and reverse HIV-related disparities at a population level.
Authors: Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden Journal: N Engl J Med Date: 2010-11-23 Impact factor: 91.245
Authors: Charlotte-Paige Rolle; Eli S Rosenberg; Aaron J Siegler; Travis H Sanchez; Nicole Luisi; Kevin Weiss; Scott Cutro; Carlos Del Rio; Patrick S Sullivan; Colleen F Kelley Journal: J Acquir Immune Defic Syndr Date: 2017-11-01 Impact factor: 3.731
Authors: Patrick J O'Connor; Jay Desai; Leif I Solberg; Laurel A Reger; A Lauren Crain; Stephen E Asche; Teresa L Pearson; Cynthia K Clark; William A Rush; Linda M Cherney; Joann M Sperl-Hillen; Donald B Bishop Journal: Diabetes Care Date: 2005-08 Impact factor: 19.112
Authors: Laura K Rusie; Carlos Orengo; Diane Burrell; Arthi Ramachandran; Magda Houlberg; Kristin Keglovitz; David Munar; John A Schneider Journal: Clin Infect Dis Date: 2018-07-02 Impact factor: 9.079
Authors: Jean-Michel Molina; Catherine Capitant; Bruno Spire; Gilles Pialoux; Laurent Cotte; Isabelle Charreau; Cecile Tremblay; Jean-Marie Le Gall; Eric Cua; Armelle Pasquet; François Raffi; Claire Pintado; Christian Chidiac; Julie Chas; Pierre Charbonneau; Constance Delaugerre; Marie Suzan-Monti; Benedicte Loze; Julien Fonsart; Gilles Peytavin; Antoine Cheret; Julie Timsit; Gabriel Girard; Nicolas Lorente; Marie Préau; James F Rooney; Mark A Wainberg; David Thompson; Willy Rozenbaum; Veronique Doré; Lucie Marchand; Marie-Christine Simon; Nicolas Etien; Jean-Pierre Aboulker; Laurence Meyer; Jean-François Delfraissy Journal: N Engl J Med Date: 2015-12-01 Impact factor: 91.245
Authors: Aaron J Siegler; Farah Mouhanna; Robertino Mera Giler; Kevin Weiss; Elizabeth Pembleton; Jodie Guest; Jeb Jones; Amanda Castel; Howa Yeung; Michael Kramer; Scott McCallister; Patrick S Sullivan Journal: Ann Epidemiol Date: 2018-06-15 Impact factor: 3.797
Authors: Susanne Doblecki-Lewis; Albert Y Liu; Daniel J Feaster; Stephanie E Cohen; Richard Elion; Oliver Bacon; Megan Coleman; Gabriel Cardenas; Michael A Kolber Journal: J Acquir Immune Defic Syndr Date: 2018-09-01 Impact factor: 3.731
Authors: Douglas S Krakower; Matthew J Mimiaga; Joshua G Rosenberger; David S Novak; Jennifer A Mitty; Jaclyn M White; Kenneth H Mayer Journal: PLoS One Date: 2012-03-28 Impact factor: 3.240
Authors: Ryan J Watson; Ethan Morgan; Charlene Collibee; Jolaade Kalinowski; Casey Cunningham; E Jennifer Edelman; Philip Chan; Lisa A Eaton Journal: Subst Use Misuse Date: 2022-08-08 Impact factor: 2.362
Authors: Susan P Buchbinder; Aaron J Siegler; Kenneth Coleman; Eric Vittinghoff; Gretchen Wilde; Annie Lockard; Hyman Scott; Peter L Anderson; Nicole Laborde; Ariane van der Straten; Richard H Christie; Michelle Marlborough; Albert Y Liu Journal: AIDS Behav Date: 2022-08-19
Authors: Alexa B D'Angelo; Javier Lopez-Rios; Anthony W P Flynn; Ian W Holloway; David W Pantalone; Christian Grov Journal: Transl Behav Med Date: 2021-03-16 Impact factor: 3.046
Authors: Nicole D Laborde; Patrick M Kinley; Matthew Spinelli; Eric Vittinghoff; Ryan Whitacre; Hyman M Scott; Susan P Buchbinder Journal: AIDS Behav Date: 2020-09
Authors: Ashley Schuyler; Zainab Alidina; M Margaret Dolcini; Gary Harper; J Dennis Fortenberry; Ryan Singh; Omar Jamil; Lance Pollack; Joseph Catania Journal: AIDS Behav Date: 2021-06-21
Authors: Meagan Zarwell; Steven A John; Drew Westmoreland; Chloe Mirzayi; David W Pantalone; Sarit Golub; Denis Nash; Christian Grov Journal: AIDS Behav Date: 2020-10-15